NEWS
SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS

Latest Updates

January 2010 Marketed Drug Updates and Additions

Brand Name

Generic Name

Other Designation

Ceplene (formerly Maxamine and EpiLeukin)

Histamine dihydrochloride

 

Herceptin

Trastuzumab

RG597, formerly rhuMAb HER2

Avastin

Bevacizumab

rhuMAb-VEGF, NSC-704865, R435, RG435

Arzerra

Ofatumumab

HuMax-CD20, GSK1841157

Gardasil, Silgard (Eastern Europe)

Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

 

Tasigna

Nilotinib

AMN107, AMN-107

Afinitor (cancer), Certican (immunosuppression)

Everolimus

RAD001, RAD001C

Zometa

Zoledronate, zoledronic acid

ZOL 446/ CGP 42446

Gleevec (USA, Canada, Israel), Glivec (Europe)

Imatinib mesylate

STI-571, STI571, formerly CGP-57148B

Xeloda

Capecitabine

Ro 09-1978, RG340

Amnolake, Amnoid, Amnoleuk, Tamibaro

Tamibarotene

Am80, Am-80, TOS-80T

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM